# US 2015/0086509 A1 · Compositions and methods for treating cancer using interferon and mapk pathway inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0086509 A1
- Document ID: US20150086509A1
- Status: Published application
- Kind: A1
- Application number: 14/496,723
- Filed: 2014-09-25
- Published: 2015-03-26
- Earliest claimed: 2013-09-25
- Assignees: The Trustees of Columbia University in the City of New York; Sloan-Kettering Institute for Cancer Research
- Applicants: The Trustees of Columbia University in the City of New York; Sloan-Kettering Institute for Cancer Research
- Inventors: Oren Litvin; Neal Rosen; Dana Pe'er
- Web page: https://patentgrep.com/patent/US20150086509A1

## CPC

- A61K 38/215: {IFN-beta}
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/212: {IFN-alpha}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57595: {involving intracellular compounds}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides for methods and compositions for treating cancer. A subject having cancer is administered an interferon and an inhibitor of mitogen-activated protein kinase (MAPK) signaling pathway. The combination of the interferon and the inhibitor of the MAPK pathway produces a synergistic effect on the cancer compared to the effect of the interferon or the inhibitor of the MAPK pathway alone. The activity of the interferon pathway, interferon expression levels and/or interferon locus copy number can be used as biomarkers for treatment of cancer by MAPK pathway inhibitors.

## Claims

### Claim 1

A method of treating cancer in a subject, comprising the step of administering to the subject an interferon and an inhibitor of mitogen-activated protein kinase (MAPK) signaling pathway, wherein the combination of the interferon and the inhibitor of the MAPK pathway produces a synergistic effect on the cancer compared to the effect of the interferon alone or the effect of the inhibitor of the MAPK pathway alone.

### Claim 2 (depends on 1)

The method of claim 1, wherein the combination results in a synergistic increase in apoptosis of cancer cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the combination results in a synergistic reduction in tumor volume.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inhibitor is an inhibitor of RAF, an inhibitor of MEK, an inhibitor of ERK, an inhibitor of RAS, an inhibitor of receptor tyrosine kinases (RTKs), or combinations thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the inhibitor is a small molecule, a polynucleotide, a polypeptide, or an antibody or antigen-binding portion thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the inhibitor is PLX4720, PD325901, GW5074, BAY 43-9006, ISIS 5132, PD98059, PD184352, U0126, Ro 09-2210, L-783,277, GSK-1120212, trametinic, vemurafenib, purvalanol, or imidazolium trans-imidazoledimethyl sulfoxide-tetrachlororuthenate (NAMI-A).

### Claim 7 (depends on 5)

The method of claim 5, wherein the polynucleotide is a small interfering RNA (siRNA) or an antisense molecule.

### Claim 8 (depends on 1)

The method of claim 1, wherein the interferon is a type I, type II or type III interferon.

### Claim 9 (depends on 8)

The method of claim 8, wherein the interferon is a type I interferon selected from the group consisting of interferon-α, interferon-β, interferon-ε, interferon-κ, and interferon-ω.

### Claim 10 (depends on 1)

The method of claim 1, wherein the interferon and the inhibitor are administered simultaneously, sequentially or separately.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer is melanoma, breast cancer, colon cancer, pancreatic cancer, cervical cancer, thyroid cancer or bladder cancer.

### Claim 12

A method of treating cancer in a subject, comprising the step of administering to the subject an interferon and a cytotoxic agent, wherein the combination of the interferon and the cytotoxic agent produces a synergistic effect on the cancer compared to the effect of the interferon alone or the effect of the cytotoxic agent alone.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cytotoxic agent is an inhibitor of MAPK signaling pathway, an alkylating agent, an anti-metabolite, an anti-microtubule agent, a topoisomerase inhibitor, a cytotoxic antibiotic, or an endoplasmic reticulum stress inducing agent.

### Claim 14 (depends on 12)

The method of claim 12, wherein the combination results in a synergistic increase in apoptosis of cancer cells.

### Claim 15 (depends on 12)

The method of claim 12, wherein the combination results in a synergistic reduction in tumor volume.

### Claim 16 (depends on 12)

The method of claim 12, wherein the interferon is a type I interferon selected from the group consisting of interferon-α, interferon-β, interferon-ε, interferon-κ, and interferon-ω.

### Claim 17

A pharmaceutical composition comprising a first amount of an interferon and a second amount of an inhibitor of the mitogen-activated protein kinase (MAPK) signaling pathway, wherein the combination of the first amount of interferon and the second amount of the inhibitor of the MAPK pathway produces a synergistic effect on cancer compared to the effect of the first amount of interferon alone or the effect of the second amount of the inhibitor of the MAPK pathway alone.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the combination results in a synergistic increase in apoptosis of cancer cells.

### Claim 19 (depends on 17)

The pharmaceutical composition of claim 17, wherein the combination results in a synergistic reduction in tumor volume.

### Claim 20 (depends on 17)

The pharmaceutical composition of claim 17, wherein the inhibitor is an inhibitor of RAF, an inhibitor of MEK, an inhibitor of ERK, an inhibitor of RAS, an inhibitor of receptor tyrosine kinases (RTKs), or combinations thereof.

### Claim 21 (depends on 17)

The pharmaceutical composition of claim 17, wherein the inhibitor is a small molecule, a polynucleotide, a polypeptide, or an antibody or antigen-binding portion thereof.

### Claim 22 (depends on 17)

The pharmaceutical composition of claim 17, wherein the inhibitor is PLX4720, PD325901, GW5074, BAY 43-9006, ISIS 5132, PD98059, PD184352, U0126, Ro 09-2210, L-783,277, GSK-1120212, trametinic, vemurafenib, purvalanol, or imidazolium trans-imidazoledimethyl sulfoxide-tetrachlororuthenate (NAMI-A).

### Claim 23 (depends on 17)

The pharmaceutical composition of claim 17, wherein the interferon is a type I interferon selected from the group consisting of interferon-α, interferon-β, interferon-ε, interferon-κ, and interferon-ω.

### Claim 24

A method of treating cancer cells, comprising the steps of:
(a) determining activity of STAT1 (Signal Transduction And Transcription 1) signaling pathway in the cancer cells; and
(b) administering to the cancer cells an inhibitor of the mitogen-activated protein kinase (MAPK) signaling pathway, if the activity of the STAT1 signaling pathway in step (a) is less than 20% of activity of STAT1 signaling pathway in WM1361 melanoma cells.

### Claim 25 (depends on 24)

The method of claim 24, wherein in step (b) an interferon is also administered.

### Claim 26 (depends on 24)

The method of claim 24, wherein in step (a) the activity of STAT signaling pathway is determined by assaying the level of pSTAT1-Y701 (STAT1 phosphorylated at Tyr701).

### Claim 27 (depends on 24)

The method of claim 24, wherein in step (a) the activity of STAT signaling pathway is determined by an assay selected from the group consisting of: (i) an assay of protein level or phosphorylation level of JAK1/2, STAT1/2 and/or interferon receptors; (ii) an assay of expression levels of STAT1/2 downstream genes; and (iii) an assay of mRNA and protein levels of interferon-α or interferon-β.

### Claim 28 (depends on 24)

The method of claim 24, wherein the inhibitor is an inhibitor of RAF, an inhibitor of MEK, an inhibitor of ERK, an inhibitor of RAS, an inhibitor of receptor tyrosine kinases (RTKs), or combinations thereof.

### Claim 29 (depends on 24)

The method of claim 24, wherein the inhibitor is a small molecule, a polynucleotide, a polypeptide, or an antibody or antigen-binding portion thereof.

### Claim 30 (depends on 24)

The method of claim 24, wherein the inhibitor is PLX4720, PD325901, GW5074, BAY 43-9006, ISIS 5132, PD98059, PD184352, U0126, Ro 09-2210, L-783,277, GSK-1120212, trametinic, vemurafenib, purvalanol, or imidazolium trans-imidazoledimethyl sulfoxide-tetrachlororuthenate (NAMI-A).

### Claim 31 (depends on 24)

The method of claim 24, wherein the interferon is a type I interferon selected from the group consisting of interferon-α, interferon-β, interferon-ε, interferon-κ, and interferon-ω.

### Claim 32 (depends on 25)

The method of claim 25, wherein the interferon and the inhibitor are administered simultaneously, sequentially or separately.

### Claim 33

A method of treating cancer cells, comprising the steps of:
(a) determining copy number of interferon locus located on chromosome 9p22 in the cancer cells;
(b) administering to the cancer cells an inhibitor of the mitogen-activated protein kinase (MAPK) signaling pathway, if the copy number of the interferon locus determined in step (a) is 0 or 1.

### Claim 34 (depends on 33)

The method of claim 33, wherein in step (b) an interferon is also administered.

### Claim 35 (depends on 33)

The method of claim 33, wherein the inhibitor is an inhibitor of RAF, an inhibitor of MEK, an inhibitor of ERK, an inhibitor of RAS, an inhibitor of receptor tyrosine kinases (RTKs), or combinations thereof.

### Claim 36 (depends on 33)

The method of claim 33, wherein the inhibitor is a small molecule, a polynucleotide, a polypeptide, or an antibody or antigen-binding portion thereof.

### Claim 37 (depends on 33)

The method of claim 33, wherein the inhibitor is PLX4720, PD325901, GW5074, BAY 43-9006, ISIS 5132, PD98059, PD184352, U0126, Ro 09-2210, L-783,277, GSK-1120212, trametinic, vemurafenib, purvalanol, or imidazolium trans-imidazoledimethyl sulfoxide-tetrachlororuthenate (NAMI-A).

### Claim 38 (depends on 33)

The method of claim 33, wherein the interferon is a type I interferon selected from the group consisting of interferon-α, interferon-β, interferon-ε, interferon-κ, and interferon-ω.

### Claim 39 (depends on 34)

The method of claim 34, wherein the interferon and the inhibitor are administered simultaneously, sequentially or separately.
